Suppr超能文献

高级别子宫内膜癌——三级癌症中心的行为表现与结局

High-Grade Endometrial Cancer-Behaviour and Outcomes at a Tertiary Cancer Centre.

作者信息

Lakhwani Prerna, Agarwal Priya, Goel Ashish, Nayar Nidhi, Pande Pankaj, Kumar Kapil

机构信息

Gynae Oncology, BL Kapur Super Specialty Hospital, Pusa Road, Delhi, India.

Surgical oncology, BL Kapur Super Specialty Hospital, Pusa Road, Delhi, India.

出版信息

Indian J Surg Oncol. 2019 Dec;10(4):662-667. doi: 10.1007/s13193-019-00970-1. Epub 2019 Aug 21.

Abstract

High-grade endometrial carcinomas are a heterogeneous group of clinically aggressive tumours. They include FIGO grade 3 endometrioid adenocarcinoma, uterine papillary serous carcinoma (UPSC), clear cell carcinoma, undifferentiated carcinoma and carcinosarcomas or malignant mixed Mullerian tumour (MMMT). The aim of this study is to look at clinicopathological features and survival outcomes of high-grade endometrial cancers of the uterus in our centre. A tertiary care centre in India. The study design is retrospective with survival analysis. We did a retrospective analysis of all patients admitted with a diagnosis of high-grade uterine carcinoma. Data regarding baseline characteristics, disease profiles, surgical outcomes, complications, extent of surgical staging, duration of surgery, blood loss, length of hospital stay, drain output, wound infection, surgico-pathological stage and grade, tumour size and location, myometrium and lymphovascular invasion, node positivity, adjuvant treatment, overall survival and recurrence-free survival. Survival analysis was done using the Kaplan-Meier method. We had 115 females diagnosed with endometrial cancer. Of these, 40 patients had high-grade endometrial cancer. Mean age at presentation was 64.7 years (range 33-80 years). Of this, endometrioid adenocarcinoma grade III was the commonest (37.5%), followed by UPSC in 32.5% and MMMT in 22.5% patients. Clear cell variant and mixed dedifferentiated variant were reported in 5% and 2.5%, respectively. Over 48 months of follow-up, recurrence was detected in eight patients (20%) and median time to recurrence was 11 months. Mean recurrence-free survival was 32.8 months and mean overall survival was 38.6 months High-grade endometrial cancers are aggressive tumours of postmenopausal women. Surgical staging and combination chemotherapy along with radiation therapy are the mainstay of treatment. In spite of adequate debulking followed by adjuvant therapy, survival remains poor.

摘要

高级别子宫内膜癌是一组临床侵袭性肿瘤的异质性群体。它们包括国际妇产科联盟(FIGO)3级子宫内膜样腺癌、子宫乳头状浆液性癌(UPSC)、透明细胞癌、未分化癌以及癌肉瘤或恶性米勒管混合瘤(MMMT)。本研究的目的是观察我们中心子宫高级别子宫内膜癌的临床病理特征和生存结局。这是印度的一家三级医疗中心。研究设计为回顾性生存分析。我们对所有诊断为高级别子宫癌的患者进行了回顾性分析。收集了有关基线特征、疾病概况、手术结果、并发症、手术分期范围、手术时长、失血量、住院时间、引流量、伤口感染、手术病理分期和分级、肿瘤大小和位置、肌层和淋巴管浸润、淋巴结阳性情况、辅助治疗、总生存期和无复发生存期的数据。使用Kaplan-Meier方法进行生存分析。我们共诊断出115例子宫内膜癌女性患者。其中,40例患有高级别子宫内膜癌。就诊时的平均年龄为64.7岁(范围33 - 80岁)。其中,III级子宫内膜样腺癌最为常见(37.5%),其次是UPSC(32.5%)和MMMT(22.5%)。透明细胞变异型和混合去分化变异型分别占5%和2.5%。在超过48个月的随访中,8例患者(20%)出现复发,复发的中位时间为11个月。平均无复发生存期为32.8个月,平均总生存期为38.6个月。高级别子宫内膜癌是绝经后女性的侵袭性肿瘤。手术分期、联合化疗以及放疗是主要的治疗方法。尽管进行了充分的肿瘤减灭术并辅以辅助治疗,但生存率仍然较低。

相似文献

1
High-Grade Endometrial Cancer-Behaviour and Outcomes at a Tertiary Cancer Centre.
Indian J Surg Oncol. 2019 Dec;10(4):662-667. doi: 10.1007/s13193-019-00970-1. Epub 2019 Aug 21.
3
Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma.
Gynecol Oncol. 2006 Nov;103(2):684-7. doi: 10.1016/j.ygyno.2006.05.009. Epub 2006 Jun 23.
4
The comparison of clinicopathological characteristics in primary malignant mixed műllerian tumour with epithelial endometrial carcinoma.
Aust N Z J Obstet Gynaecol. 2012 Feb;52(1):44-8. doi: 10.1111/j.1479-828X.2011.01389.x. Epub 2011 Dec 20.
6
Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapy.
Int J Gynecol Cancer. 2020 Jan;30(1):48-55. doi: 10.1136/ijgc-2019-000675. Epub 2019 Nov 12.
7
8
Which is worse: uterine papillary serous carcinomas or carcinosarcomas?
J Gynecol Oncol. 2011 Jun 30;22(2):83-8. doi: 10.3802/jgo.2011.22.2.83.
9
Uterine papillary serous carcinoma pre-operatively diagnosed as endometrioid carcinoma: Is omentectomy necessary?
Aust N Z J Obstet Gynaecol. 2015 Oct;55(5):498-502. doi: 10.1111/ajo.12377. Epub 2015 Jul 31.
10
Clinical Profile and Treatment Outcomes of Malignant Mixed Mullerian Tumors of the Uterus: A Single-Center Experience.
Cureus. 2023 Oct 31;15(10):e48079. doi: 10.7759/cureus.48079. eCollection 2023 Oct.

引用本文的文献

1
Clinicopathological Profile of Carcinoma Endometrium in a Single Institution of Kerala, India.
J Midlife Health. 2025 Jan-Mar;16(1):96-102. doi: 10.4103/jmh.jmh_191_24. Epub 2025 Apr 5.
3
Dedifferentiated endometrial carcinoma metastasis to axillary lymph node: a case report.
J Med Case Rep. 2023 Oct 30;17(1):451. doi: 10.1186/s13256-023-04192-6.

本文引用的文献

1
Outcomes of carcinosarcoma in a tertiary care institution in India.
South Asian J Cancer. 2018 Jan-Mar;7(1):31-33. doi: 10.4103/sajc.sajc_243_16.
2
An analysis of current treatment practice in uterine papillary serous and clear cell carcinoma at two high volume cancer centers.
J Gynecol Oncol. 2015 Jan;26(1):25-31. doi: 10.3802/jgo.2015.26.1.25. Epub 2014 Nov 6.
4
Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma.
Am J Obstet Gynecol. 2014 Apr;210(4):363.e1-363.e10. doi: 10.1016/j.ajog.2013.12.025. Epub 2013 Dec 19.
5
Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol. 2013 Oct;24 Suppl 6:vi33-8. doi: 10.1093/annonc/mdt353.
6
Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial.
Gynecol Oncol. 2013 May;129(2):277-84. doi: 10.1016/j.ygyno.2013.02.023. Epub 2013 Feb 26.
8
Recurrent endometrial cancer: patterns of recurrent disease and assessment of prognosis.
Clin Radiol. 2007 Jan;62(1):28-34; discussion 35-6. doi: 10.1016/j.crad.2006.06.015.
10
Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium.
Gynecol Oncol. 2004 Dec;95(3):593-6. doi: 10.1016/j.ygyno.2004.08.019.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验